Clinical Validation For LOXO-101 Against TRK Fusion Cancer
Sunday, August 2, 2015 - 13:30
in Health & Medicine
Loxo Oncology, Inc. and The University of Colorado Cancer Center today announced the publication of a research brief describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development. Additional contributors to the paper include the Knight Cancer Institute at Oregon Health&Science University and Foundation Medicine, Inc. (Nasdaq:FMI). read more